Triple
T23186613
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | REGN |
E579608
|
entity |
| Predicate | hasUnderlyingCompanyExchangeListing |
P105085
|
FINISHED |
| Object | NASDAQ:REGN |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: NASDAQ:REGN | Statement: [REGN, hasUnderlyingCompanyExchangeListing, NASDAQ:REGN]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: NASDAQ:REGN Context triple: [REGN, hasUnderlyingCompanyExchangeListing, NASDAQ:REGN]
-
A.
REGN
chosen
REGN is the stock ticker symbol for Regeneron Pharmaceuticals, a major U.S.-based biotechnology company known for developing innovative antibody-based therapies.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
D.
United Therapeutics
United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other serious cardiopulmonary conditions.
-
E.
Celgene
Celgene is a biopharmaceutical company known for developing innovative therapies for cancer and inflammatory disorders.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasUnderlyingCompanyExchangeListing Context triple: [REGN, hasUnderlyingCompanyExchangeListing, NASDAQ:REGN]
-
A.
hasUnderlyingCompanyPrimaryListing
Indicates that an entity is associated with the company where that company’s primary stock exchange listing is held.
-
B.
underlyingCompanyExchange
Indicates that one entity is the stock exchange on which the underlying company of another financial instrument or contract is listed or traded.
-
C.
underlyingCompanyStockExchangeCountry
Indicates the country in which the stock exchange is located on which the underlying company’s shares are traded.
-
D.
hasUnderlyingCompanySecondaryMarket
Indicates that an entity is associated with a secondary market that trades interests in its underlying company.
-
E.
underlyingCompanyExchangeCode
chosen
Indicates the stock exchange code on which the underlying company’s securities are listed or traded.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
| PD | Predicate disambiguation | batch_69ef8a041c0081909afb670d17a5aaba |
completed | April 27, 2026, 4:08 p.m. |
Created at: April 17, 2026, 4:05 p.m.